BRIEF published on 02/20/2026 at 07:05, 12 days 15 hours ago BB Biotech AG Releases 2025 Annual Report Dividend Proposal Biotechnology Sector Net Profit Increase BB Biotech 2025 Annual Report
BRIEF published on 02/20/2026 at 07:05, 12 days 15 hours ago BB Biotech's 2025 Annual Report Highlights Strong Financial Gains Annual Report Portfolio Value Shareholder Returns BB Biotech Financial Gains
PRESS RELEASE published on 02/20/2026 at 07:00, 12 days 15 hours ago EQS-Adhoc: BB Biotech AG publishes its 2025 annual report BB Biotech AG releases its 2025 annual report, reporting a strong performance with a +34.2% total return in CHF. The annual report includes detailed information on the biotechnology sector and the company's investments Financial Results Investment BB Biotech AG Biotechnology Sector 2025 Annual Report
PRESS RELEASE published on 02/20/2026 at 07:00, 12 days 15 hours ago Annual Report 2025: BB Biotech delivers strong performance and portfolio value realization BB Biotech AG's Annual Report 2025 showcases strong performance and portfolio value realization. Shareholder returns, active capital management, and refined investment processes highlighted BB Biotech AG Portfolio Value Shareholder Returns Annual Report 2025 Investment Processes
BRIEF published on 01/23/2026 at 07:05, 1 month 12 days ago BB Biotech AG Reports Significant Profit for 2025 Investment Company BB Biotech AG Drug Developers 2025 Profit Share Price Development
BRIEF published on 01/23/2026 at 07:05, 1 month 12 days ago BB Biotech Reports Strong Preliminary 2025 Results and Dividend Proposal Dividend Proposal Share Performance BB Biotech Biotech Investment 2025 Financial Results
PRESS RELEASE published on 01/23/2026 at 07:00, 1 month 12 days ago EQS-Adhoc: BB Biotech AG closes the 2025 fiscal year with a profit BB Biotech AG closes the 2025 fiscal year with a profit of approximately CHF 578 million, reflecting share price development. Full report on Feb 20, 2026 BB Biotech AG Profit 2025 Fiscal Year Share Price Development CHF 578 Million
PRESS RELEASE published on 01/23/2026 at 07:00, 1 month 12 days ago BB Biotech: Preliminary full-year 2025 results and dividend proposal BB Biotech AG reports strong full-year 2025 results with +34.2% total return in CHF, +37.0% in EUR, and +53.7% in USD, proposes dividend of CHF 2.25 per share at AGM on March 19, 2026 Dividend Proposal Stock Market Full-year Results BB Biotech AG 2025 Performance
BRIEF published on 10/28/2025 at 13:20, 4 months 7 days ago BB Biotech Outperforms with Strong Q3 2025 Results Biotech Sector M&A BB Biotech Q3 2025 Nasdaq Biotech Index
PRESS RELEASE published on 10/28/2025 at 13:15, 4 months 7 days ago Edison issues report on BB Biotech (BION) Edison issues positive report on BB Biotech (BION) with strong Q325 results, outperforming its benchmark. Sector outlook remains favorable with M&A as key performance driver Edison M&A BB Biotech Outperforming Q325 Results
Published on 03/04/2026 at 22:00, 31 minutes ago NioCorp to Host Live Webinar on Construction of Elk Creek Critical Minerals Project Mine Portal
Published on 03/04/2026 at 15:00, 7 hours 31 minutes ago Commencement of Ground-Based Geophysical Programme
Published on 03/04/2026 at 15:00, 7 hours 31 minutes ago iAccess Alpha Virtual Best Ideas Spring Investment Conference 2026
Published on 03/04/2026 at 14:15, 8 hours 16 minutes ago Congressman Adrian Smith Starts Dig of NioCorp's Elk Creek Project Mine Portal
Published on 03/04/2026 at 19:30, 3 hours 1 minute ago EEII AG: Extraordinary General Meeting on March 26, 2026, to approve the capital increase
Published on 03/04/2026 at 18:55, 3 hours 36 minutes ago Fuller, Smith & Turner PLC: Transaction in own shares
Published on 03/04/2026 at 18:38, 3 hours 53 minutes ago Fuller, Smith & Turner PLC: Director / PDMR Shareholding
Published on 03/04/2026 at 18:30, 4 hours 1 minute ago Avolta extends concessions for 45 travel retail and F&B stores at Zurich Airport
Published on 03/04/2026 at 18:20, 4 hours 11 minutes ago EQS-Adhoc: Gabler Group AG sets final offer price for initial public offering (IPO) at EUR 44.00 per share
Published on 03/04/2026 at 18:00, 4 hours 31 minutes ago Disclosure of Share Capital and Voting Rights as of February 28, 2026
Published on 03/04/2026 at 17:45, 4 hours 46 minutes ago MONTHLY INFORMATION RELATING TO THE TOTAL NUMBER OF VOTING RIGHTS AND SHARES MAKING UP THE SHARE CAPITAL
Published on 03/04/2026 at 17:45, 4 hours 46 minutes ago Information concerning the total number of voting rights and shares 2026 02 28
Published on 03/04/2026 at 17:45, 4 hours 46 minutes ago MONTHLY INFORMATION RELATING TO THE TOTAL NUMBER OF VOTING RIGHTS AND SHARES MAKING UP THE SHARE CAPITAL
Published on 03/04/2026 at 17:35, 4 hours 56 minutes ago Disclosure of the number of shares and the total number of voting rights as of February 28, 2026
